The Washington Post reports that US Department of Agriculture researchers will no longer have to label their peer-reviewed articles as "preliminary."
Though the test is already commercially available, the firm met with the FDA last year to discuss plans for a randomized controlled trial to support regulatory approval.
MSK researchers showed that high TMB may be associated with improved survival across tumor types, but the cut-offs for high and low status will vary based on histology.
Data from the GUIDED study will be central to commercial payor discussions, a Medicare LCD reconsideration request, and eventually expansion into the primary care market.
The investment bank upgraded the company's stock to an Outperform rating from Market Perform but lowered its price target to $37 per share.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
Following a pilot project, Genome Biology is to adopt a transparent peer review process at the beginning of 2019.
Indiana University School of Medicine's Aaron Carroll discusses the flaws and ways to improve peer review at the New York Times.
One of the largest repositories of molecular brain cancer data in the world, the enhanced REMBRANDT is more comprehensive than an earlier NCI-hosted version.
A pair of researchers has found that retracted papers are often still cited and call for them to be harder to access, Retraction Watch reports.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.